Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection

AIDS Research and Therapy

Volumn 13, Issue 1, 2016, Pages

  Tincati, Camilla ^a   Douek, Daniel C ^b   Marchetti, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Gastrointestinal barrier; Microbial translocation; Microbiota; Mucosal immunity

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22;

BACTERIAL TRANSLOCATION; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; DYSBIOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; METABOLIC ACTIVATION; MORBIDITY; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; DISEASE COURSE; GASTROINTESTINAL TRACT; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE ACTIVATION; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

BACTERIAL TRANSLOCATION; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION;

EID: 84962920643     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-016-0103-1     Document Type: Review

References (76)

1. Liu Z, Hultin LE, Cumberland WG, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+T cells is a marker of poor prognosis in HIV infection: results of 6years of follow-up. Cytometry. 1996;26:1-7.
2. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-70.
3. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+T-cell changes independent of viral load. Blood. 2004;104:942-7.
4. Marchetti G, Bellistrì GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22:2035-8.
5. Estes JD, Harris LD, Klatt NR, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6:e1001052.
6. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71.
7. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780-90.
8. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+cell count. AIDS. 2011;25:1385-94.
9. León A, Leal L, Torres B, et al. Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. AIDS. 2015;29:675-81.
10. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228-38.
11. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248-59.
12. Kim CJ, Kovacs C, Chun TW, et al. Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions. J Acquir Immune Defic Syndr. 2014;67:514-8.
13. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Pre-cART pro-inflammatory milieu, microbial translocation (MT) and risk of disease progression in HIV-infected patients starting their first cART: data from the Icona foundation cohort. In: European AIDS Clinical Society (EACS), Barcelona; 2015.
14. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6:e1000852.
15. Kristoff J, Haret-Richter G, Ma D, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014;124:2802-6.
16. Smith AJ, Schacker TW, Reilly CS, Haase AT. A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection. J Acquir Immune Defic Syndr. 2010;55:306-15.
17. Perkins MR, Bartha I, Timmer JK, et al. The interplay between host genetic variation, viral replication, and microbial translocation in untreated HIV-infected individuals. J Infect Dis. 2015;212:578-84.
18. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-43.
19. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS. 2006;20:1727-36.
20. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177-85.
21. Chevalier MF, Petitjean G, Dunyach-Rémy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog. 2013;9:e1003453.
22. Jenabian MA, El-Far M, Vyboh K, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis. 2015;212:355-66.
23. Streeck H, Kwon DS, Pyo A, et al. Epithelial adhesion molecules can inhibit HIV-1-specific CD8+T-cell functions. Blood. 2011;117:5112-22.
24. Chung CY, Alden SL, Funderburg NT, Fu P, Levine AD. Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+individuals. PLoS Pathog. 2014;10:e1004198.
25. Voigt RM, Keshavarzian A, Losurdo J, et al. HIV-associated mucosal gene expression: region-specific alterations. AIDS. 2015;29:537-46.
26. Tincati C, Merlini E, Braidotti P, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+T-cell recovery upon virologically-suppressive cART. AIDS. 2016;30(7):991-1003. doi: 10.1097/QAD.0000000000001015.
27. Somsouk M, Estes JD, Deleage C, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015;29:43-51.
28. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10:e1004543.
29. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+T cells. Nature. 2002;417:95-8.
30. Gosselin A, Monteiro P, Chomont N, et al. Peripheral blood CCR4+CCR6+and CXCR3+CCR6+CD4+T cells are highly permissive to HIV-1 infection. J Immunol. 2010;184:1604-16.
31. Wacleche VS, Chomont N, Gosselin A, et al. The colocalization potential of HIV-specific CD8+and CD4+T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid. PLoS ONE. 2012;7:e32964.
32. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093-7.
33. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-59.
34. Costiniuk CT, Angel JB. Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol. 2012;5:596-604.
35. Allers K, Puyskens A, Epple HJ, et al. The effect of timing of antiretroviral therapy on CD4(+) T-cell reconstitution in the intestine of HIV-infected patients. Mucosal Immunol. 2015;9(1):265-74.
36. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170:2106-12.
37. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534-44.
38. Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+DCs and IL-17+and IL-22+lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 2012;5:646-57.
39. Page EE, Greathead L, Metcalf R, et al. Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection. J Acquir Immune Defic Syndr. 2014;67:227-35.
40. Kök A, Hocqueloux L, Hocini H, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol. 2015;8:127-40.
41. d'Ettorre G, Baroncelli S, Micci L, et al. Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial. PLoS ONE. 2014;9:e109791.
42. Kim CJ, McKinnon LR, Kovacs C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol. 2013;191:2164-73.
43. Monteiro P, Gosselin A, Wacleche VS, et al. Memory CCR6+CD4+T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7. J Immunol. 2011;186:4618-30.
44. DaFonseca S, Niessl J, Pouvreau S, et al. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015;12:38.
45. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2:ra3632.
46. Gaardbo JC, Trøsied M, Stiksrud B, et al. Increased Tryptophan Catabolism Is Associated With Increased Frequency of CD161+Tc17/MAIT Cells and Lower CD4+T-Cell Count in HIV-1 Infected Patients on cART After 2 Years of Follow-Up. J Acquir Immune Defic Syndr. 2015;70:228-35.
47. Byakwaga H, Boum Y, Huang Y, et al. The kynurenine pathway of tryptophan catabolism, CD4+T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014;210:383-91.
48. Chen J, Shao J, Cai R, et al. Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients. PLoS ONE. 2014;9:e100446.
49. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2015;65(2):330-9.
50. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46:757-8.
51. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr. 2011;57:363-70.
52. Merlini E, Bai F, Bellistrì GM, Tincati C, d' Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS ONE. 2011;6:e18580.
53. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra91.
54. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014;7:983-94.
55. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.
56. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211:19-27.
57. Pérez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS. 2013;27:1921-31.
58. Klase Z, Ortiz A, Deleage C, et al. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol. 2015;8:1009-20.
59. McHardy IH, Li X, Tong M, et al. HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome. 2013;1:26.
60. Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015;8:760-72.
61. Gori A, Rizzardini G, Van't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 2011;4:554-63.
62. Cahn P, Ruxrungtham K, Gazzard B, et al. The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis. 2013;57:139-46.
63. Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903-7.
64. Vujkovic-Cvijin I, Swainson LA, Chu SN, et al. Gut-Resident Lactobacillus Abundance Associates with IDO1 Inhibition and Th17 Dynamics in SIV-Infected Macaques. Cell Rep. 2015;13(8):1589-97.
65. Villar-García J, Hernández JJ, Güerri-Fernández R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr. 2015;68:256-63.
66. d'Ettorre G, Ceccarelli G, Giustini N, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the "Probio-HIV" clinical trial. PLoS ONE. 2015;10:e0137200.
67. Stiksrud B, Nowak P, Nwosu FC, et al. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr. 2015;70:329-37.
68. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890.
69. Pallikkuth S, Micci L, Ende ZS, et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS Pathog. 2013;9:e1003471.
70. Ortiz AM, Klase ZA, DiNapoli SR, et al. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal Immunol. 2015;9(2):458-67.
71. Micci L, Ryan ES, Fromentin R, et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest. 2015;125:4497-513.
72. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549-54.
73. Somsouk M, Dunham RM, Cohen M, et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+T cell recovery: a randomized crossover trial. PLoS ONE. 2014;9:e116306.
74. Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy-ACTG A5286. J Infect Dis. 2014;211(5):780-90.
75. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
76. Savarino A, Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology. 2015;12:51.